The Daily Toke

March 17, 2026

Significant marijuana law changes are taking effect in Ohio this week under Senate Bill 56, but cannabis advocates are already mobilizing to reverse them. The legislation, approved by state lawmakers last year, has sparked a petition drive aimed at overturning the new rules—marking the latest flashpoint in an increasingly fragmented state-by-state cannabis landscape where policies shift dramatically depending on geography and political winds.

Meanwhile, Pennsylvania is moving in a different direction. State Sen. Dan Laughlin (R-Erie) shepherded an amended cannabis regulation bill through committee with a 10-1 vote, designed to create a Cannabis Control Board that would oversee both medical cannabis and intoxicating hemp products. 💰 MONEY MOVES The timing is strategic: the amendments align state law with a pending federal policy change set to take effect in November that would effectively reshape the hemp market, and Laughlin's bill positions Pennsylvania to regulate what he calls a "fragmented" marketplace that has "struggled to keep pace" with rapid industry evolution. The revised Senate Bill 49 maintains its core mission—preparing Pennsylvania's regulatory infrastructure for eventual adult-use legalization—while addressing what industry observers call a critical gap. Nicholas Rassler, Trulieve Pennsylvania's Director of Operations, noted the bill "has some potential to support both medical and adult use," while Pennsylvania Cannabis Coalition Executive Director Meredith Buettner emphasized that an independent regulatory body could "constantly review new science" and establish consistent safety standards across production and lab testing.

Pennsylvania Gov. Josh Shapiro publicly backed recreational legalization during his 2026 budget address, yet the state remains in a holding pattern nearly a decade after medical cannabis became legal. Of the six states bordering Pennsylvania, five have legalized recreational cannabis in the last six years—a fact not lost on industry experts who argue Pennsylvania can learn from neighboring markets' successes and missteps. Laughlin himself frames the case plainly: many people already use cannabis without legal protections. "🤔 THINK ABOUT IT Making it 'safe, legal and in a controlled environment,' as Laughlin argues, contrasts sharply with prohibition's track record of pushing users into unregulated markets where product safety, potency labeling, and lab testing remain unknown variables.

🚀 THIS IS COOL On the broader psychoactive landscape, a new study found that psilocybin usage rose after state decriminalization—evidence that policy shifts correlate with measurable changes in public behavior and access patterns. Meanwhile, Ohio's legislative battle signals that the cannabis normalization process remains contested ground where advocates and lawmakers disagree fundamentally on regulatory approach, even as the plant's medical applications continue to gain scientific credibility and veteran communities rely on THC products for PTSD and chronic pain management.

The pattern emerging across 2026 is clear: states are fracturing into competing regulatory models. Some, like Pennsylvania, are building independent oversight structures designed to accommodate both medical and eventual adult-use markets. Others, like Ohio, are tightening restrictions in response to what lawmakers view as market chaos. Federal policy changes looming in November add another layer of uncertainty, particularly for hemp-derived THC products that currently operate in a gray zone between state and federal authority. For patients, consumers, and businesses operating across state lines, these divergent policies create a patchwork that rewards some jurisdictions while penalizing others—a situation that may persist until federal rescheduling forces a genuine national realignment.

March 17, 2026

Multiple states are moving aggressively to ban intoxicating hemp products, creating a patchwork of restrictions that will reshape the cannabis and hemp markets across the country just as a federal policy shift looms in November. Texas is leading the charge with an absolute deadline: smokable hemp products become illegal on March 31, 2026—just two and a half weeks away. The Texas Department of State Health Services finalized new rules in early March that redefine how THC is measured in hemp products, accounting for both delta-9 THC and the conversion rate of THCA (tetrahydrocannabinol acid), which breaks down into THC at roughly an 88% rate when smoked. 💰 MONEY MOVES The hemp industry is facing catastrophic disruption. Mark Bordas, executive director of the Texas Hemp Business Council, estimates the industry generates $10–12 billion annually and employs over 50,000 Texans. Individual store operators predict 60–70% revenue declines within three weeks, with some prepared to close entirely. While intoxicating drinks and edibles will remain legal in Texas, smokable hemp—the most commonly ordered product in most stores—will vanish from shelves.

Pennsylvania is taking a similar but broader approach. The state Senate Law and Justice Committee voted 10–1 to amend Senate Bill 49, expanding the proposed Cannabis Control Board's authority to ban most hemp THC products in alignment with pending federal hemp definition changes. Sen. Dan Laughlin, who chairs the committee and sponsors the bill, frames the move as closing regulatory loopholes and preparing the state for eventual adult-use legalization. The revised bill still creates the foundational oversight structure, but now explicitly targets intoxicating hemp products that have "flooded the marketplace with little oversight" since the 2018 Farm Bill legalized hemp at the federal level.

Rhode Island's Cannabis Control Commission has recommended a statewide ban on THC-infused beverages in bars and restaurants, sparking pushback from the hospitality industry. Between August 2024 and July 2025, over 100 retailers obtained licenses to sell intoxicating THC drinks before the commission paused new licensing "in furtherance of public health and safety." The commission's final report, submitted to the General Assembly on March 1, recommends codifying restrictions on THC drinks at any venue with a liquor license. Farouk Rajab, president and CEO of the Rhode Island Hospitality Association, called the recommendation unfair targeting, arguing establishments would comply with regulations. Carla Aveledo, the commission's chief of policy, countered that all retailers selling intoxicating hemp products should face "similar high safety standards as cannabis retailers."

South Carolina Republicans are divided on how restrictive hemp bans should be. A current proposal would prohibit THC drinks from bars and restaurants while banning tinctures, gummies, and most edibles outright. Low-dose drinks could be sold in grocery stores and gas stations, while higher-dose beverages would be restricted to liquor stores. The debate reflects a larger tension: states want to regulate hemp products but disagree on how much should be permitted and where. 🤔 THINK ABOUT IT All these bans cite public health and safety, yet alcohol—which causes roughly 95,000 deaths annually in the United States—remains fully legal and sold at every corner store, while hemp products have never caused a single recorded overdose death in human history.

The coordinated wave of hemp restrictions across multiple states reflects pressure from two directions: incoming federal policy changes scheduled for November 2026, and mounting opposition from the recreational cannabis industry, which views intoxicating hemp products as market competition outside regulated dispensaries. Pennsylvania's federal alignment argument, Rhode Island's safety standards language, and South Carolina's venue-based restrictions all share common ground: the legal hemp market that emerged after 2018 has outpaced regulatory capacity, and states are scrambling to reassert control before federal law changes the entire definition of what qualifies as hemp. What remains unclear is whether these state-level bans will survive legal challenges or become models for national hemp policy as lawmakers prepare for potential adult-use legalization that could transform cannabis markets entirely.

March 17, 2026

Large-scale analysis of medicinal cannabis research finds no evidence the drug effectively treats anxiety, depression, or PTSD—three of the leading reasons doctors prescribe it—raising serious questions about how cannabis-based medicines have been approved and distributed without rigorous clinical validation.

The landmark review, published Monday in Lancet Psychiatry, analyzed 54 randomized controlled trials spanning 1980 to 2025. Researchers found cannabis showed no effect for anxiety disorders, PTSD, anorexia nervosa, or psychotic disorders like schizophrenia. None of the trials even tested cannabis for depression specifically, yet it remains one of the most common reasons people seek the treatment. The research comes as medicinal cannabis use has exploded: more than 700,000 Australians have used cannabis for health reasons in the past year alone, with sales increasing four-fold since 2022. In the United States, 40 states plus Washington D.C. have legalized medical cannabis, with more than a dozen explicitly allowing it for PTSD treatment, and countless others covering anxiety and depression under broader qualifying conditions.

Dr. Jack Wilson, lead author at the University of Sydney's Matilda Centre, emphasized the troubling regulatory gap: most cannabis products prescribed in Australia aren't registered with the Therapeutic Goods Administration, meaning they've bypassed the rigorous testing required of other medications. "The cannabis for medical use has been rolled out completely backward from how medications are typically brought to market," said psychologist Tory Spindle of Johns Hopkins, who studies cannabis pharmacology. Normally, a new medicine must complete at least one randomized controlled trial before FDA approval. Cannabis, however, operates differently—it remains federally illegal, placing regulation in individual state hands, and doctors can prescribe it for conditions based on state law without the evidence typically required.

The research did identify some limited benefits: medicinal cannabis may help reduce cannabis use among those with cannabis use disorder (similar to how methadone treats opioid addiction), and showed low-quality evidence for potential benefits in autism, insomnia, and tics. 🚀 THIS IS COOL Cannabis has demonstrated genuine effectiveness for reducing seizures in certain forms of epilepsy, managing spasticity in multiple sclerosis patients, and treating specific pain conditions—areas where evidence is substantially stronger. But for mental health specifically, the picture is stark: while roughly 27 percent of people aged 16–65 in the United States and Canada use cannabis for medical purposes, about half cite mental health management as their reason, despite the absence of clinical proof.

🤔 THINK ABOUT IT We're witnessing a regulatory inversion: alcohol kills approximately 95,000 Americans annually and is fully legal; prescription opioids kill 16,000-plus per year and are FDA-approved; cannabis has zero recorded overdose deaths in human history, yet remains federally controlled and prescribed for conditions where evidence of effectiveness doesn't exist. Dr. Wilson warned that routine medicinal cannabis use could be doing more harm than good—worsening mental health outcomes through increased psychotic symptoms and cannabis use disorder risk while delaying access to treatments with proven efficacy. The evidence suggests the real crisis isn't cannabis itself; it's the gap between how this plant has been made available to patients and the scientific standards applied to every other medication.

March 17, 2026

Texas regulators just finalized a sweeping ban on smokable cannabis products, effective March 31—just three weeks away. The Texas Department of State Health Services adopted new rules that will essentially eliminate hemp flower and smokable extracts from legal store shelves across the state, though edibles and infused drinks will remain available. The change hinges on a shift in how the state measures THC content. Previously, products were legal if they contained less than 0.3% Delta-9 THC by weight. Under the new rules, regulators will now calculate "total THC"—meaning they'll count both Delta-9 and THCA, a non-psychoactive compound that converts to Delta-9 when heated at roughly an 88% conversion rate. This technical change effectively eliminates nearly all legally compliant smokable products from the market, since hemp flower naturally contains THCA levels that push total THC well above the 0.3% threshold once conversion is factored in.

💰 MONEY MOVES The financial impact on Texas's estimated $10–12 billion hemp industry is staggering. Smokable products represent the majority of retail sales—operators estimate 60–70% of their revenue comes from flower and extracts. Retail licensing fees are jumping from $150 annually to $5,000 per location, while manufacturers will pay $10,000 per facility, up from $250. The Texas Hemp Business Council's executive director, Mark Bordas, emphasized the scale: "You're talking about shuttering stores—if these stay in place—that employ over 50,000 Texans." Some business owners have already indicated they'll close entirely rather than pivot to edibles-only operations. One anonymous hemp shop owner told reporters: "For many small retailers across Texas—including my own vape shop—these rules will effectively shut down our businesses overnight." The disposal of existing smokable inventory remains unresolved; vendors and retailers are stuck holding products that become worthless contraband in just weeks, with no clear guidance on legal disposal.

The timeline for implementation is brutal. Dispensary owners like Kallan Salganik, who runs Treehouse Dispensary in Waco, point out that changing packaging to meet new childproof container requirements, sourcing compliant inventory, and absorbing the fee increases cannot realistically happen in two to three weeks. Salganik agreed the regulations address legitimate concerns—childproof containers make sense—but argued the compressed timeline is unrealistic: "We've got to change all our packaging. That can't be done in two weeks. I can't even get a lot of the packaging shipped here and landed here in two weeks." He also questioned the fee structure relative to comparable industries. The annual $5,000 retail fee dwarfs the $3,000 biennial license cost for breweries through the Texas Alcoholic Beverage Commission, meaning THC manufacturers pay $17,000 more annually than large alcohol producers like Anheuser-Busch for the ability to operate.

Beyond the March 31 deadline, hemp businesses are bracing for increased law enforcement action. Since August 2024, local police and federal DEA agents have conducted more than 15 raids on hemp retailers across Texas, seizing products and cash that remain unrecovered in many cases. Attorneys for targeted businesses worry the new regulations—which many argue set compliance standards that are nearly impossible to meet—will trigger a spike in raids. 🤔 THINK ABOUT IT The raids have occurred despite businesses attempting to stay compliant through legal counsel, independent testing, and rigorous vetting of distributors. If the new rules eliminate most products from the legal marketplace, what happens to the unmet demand? Hemp industry advocates and cannabis policy experts warn that pushing consumers away from tested, regulated products drives them toward untested, unregulated alternatives sold through illicit channels—precisely the opposite of public health goals. The regulatory framework that emerges after March 31 will shape whether Texas's hemp market transitions to compliance, shrinks dramatically, or simply moves underground.